High Growth Tech Stocks In Asia To Watch August 2025
Top 10 High Growth Tech Companies In Asia
Name
Revenue Growth
Earnings Growth
Growth Rating
Accton Technology
22.79%
22.79%
★★★★★★
Shanghai Huace Navigation Technology
25.38%
24.34%
★★★★★★
PharmaEssentia
31.60%
57.71%
★★★★★★
Fositek
31.69%
39.80%
★★★★★★
Gold Circuit Electronics
26.63%
32.83%
★★★★★★
Eoptolink Technology
32.53%
32.58%
★★★★★★
eWeLLLtd
24.95%
24.40%
★★★★★★
Shengyi Electronics
26.23%
37.08%
★★★★★★
Naruida Technology
47.72%
54.38%
★★★★★★
CARsgen Therapeutics Holdings
81.53%
96.08%
★★★★★★
Click here to see the full list of 172 stocks from our Asian High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Beijing LongRuan Technologies
Simply Wall St Growth Rating: ★★★★★☆
Overview: Beijing LongRuan Technologies Inc. offers software solutions and IT services centered around geographic information systems for the coal industry, with a market capitalization of CN¥2.58 billion.
Operations: The company specializes in GIS-based software and IT services tailored for the coal sector. It focuses on leveraging geographic information systems to enhance operational efficiencies within the industry.
Beijing LongRuan Technologies, a standout in the high-growth tech sector in Asia, showcases robust potential with expected annual revenue and earnings growth rates of 39.4% and 68.4%, respectively, significantly outpacing the Chinese market averages of 12.7% and 23.8%. Despite a challenging past year where net profit margins dipped to 9.4% from a previous 21.5%, the company's commitment to innovation is evident in its R&D investments, aligning with industry shifts towards more sustainable growth models like SaaS which promise recurring revenue streams. The firm's strategic focus on enhancing its software solutions could well position it favorably within Asia's competitive tech landscape, promising an intriguing future trajectory despite current volatility in profit margins.
Unlock comprehensive insights into our analysis of Beijing LongRuan Technologies stock in this health report.
Understand Beijing LongRuan Technologies' track record by examining our Past report.
Beijing Infosec TechnologiesLtd
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Beijing Infosec Technologies Co., Ltd. develops and provides application security products in China, with a market cap of CN¥3.80 billion.
Operations: Beijing Infosec Technologies Co., Ltd. focuses on developing and providing application security products within China. The company operates in the cybersecurity sector, emphasizing the creation of solutions that protect applications from various threats.
Beijing Infosec TechnologiesLtd, amidst a volatile market, demonstrates promising growth with an annual revenue increase of 16.3%, surpassing China's average of 12.7%. The company is on a trajectory to profitability within three years, bolstered by a significant projected earnings growth rate of nearly 70% annually. Investing heavily in R&D, the firm aligns with evolving industry trends like SaaS models, ensuring potential for sustained income through subscriptions. This strategic focus might cushion the impact of its currently low Return on Equity at 2.7%, positioning it well for future competitiveness in Asia's tech arena.
Get an in-depth perspective on Beijing Infosec TechnologiesLtd's performance by reading our health report here.
Gain insights into Beijing Infosec TechnologiesLtd's historical performance by reviewing our past performance report.
Jiangsu Smartwin Electronics TechnologyLtd
Simply Wall St Growth Rating: ★★★★★☆
Overview: Jiangsu Smartwin Electronics Technology Co., Ltd. manufactures and sells liquid crystal displays and display modules both in China and internationally, with a market cap of CN¥3.29 billion.
Operations: Smartwin Electronics generates revenue primarily from the sale of electronic components and parts, totaling CN¥857.07 million. The company's operations focus on liquid crystal displays and display modules for both domestic and international markets.
Jiangsu Smartwin Electronics TechnologyLtd, amidst a backdrop of robust sectoral growth, has outpaced many with a notable annual revenue increase of 30.4%, significantly higher than the industry average in China. With an earnings surge of 22.1% over the past year and projections set at an impressive 40.1% annual growth, the company's strategic investment in R&D is evidently paying off, positioning it well within the high-demand electronics market. Recent affirmations of a generous dividend and shareholder-focused decisions underscore its commitment to returning value while aggressively pursuing expansion and innovation strategies that could shape its trajectory in Asia's tech landscape.
Delve into the full analysis health report here for a deeper understanding of Jiangsu Smartwin Electronics TechnologyLtd.
Review our historical performance report to gain insights into Jiangsu Smartwin Electronics TechnologyLtd's's past performance.
Where To Now?
Click this link to deep-dive into the 172 companies within our Asian High Growth Tech and AI Stocks screener.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Ready To Venture Into Other Investment Styles?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SHSE:688078 SHSE:688201 and SZSE:301106.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Needham Maintains Buy Rating on The Walt Disney Company (DIS) Stock
The Walt Disney Company (NYSE:DIS) is one of the Reddit Stocks with the Highest Upside Potential. On August 7, Laura Martin from Needham maintained a 'Buy' rating on the company's stock, with a price objective of $125.00. The analyst's rating is backed by several positive developments for The Walt Disney Company (NYSE:DIS) in Q3 2025. Notably, the company's diluted EPS rose to $2.92 from $1.43 in Q3 2024, and adjusted EPS went up by 16% for Q3 2025 to $1.61 from $1.39 in Q3 2024. A packed theater of moviegoers watching a blockbuster film produced by the entertainment company. Furthermore, The Walt Disney Company (NYSE:DIS)'s direct-to-consumer segment demonstrated profitability with an operating income of $346 million. The company's Experiences segment saw operating income of $2.5 billion, reflecting a rise of $294 million compared to Q3 2024. The operating income in the quarter demonstrates a ~$40 million benefit from the timing of the Easter holiday, and a ~$30 million impact from pre-opening expenses at Disney Cruise Line. Despite the concerns, the positive financial performance and strategic initiatives, like asset swap involving ESPN and the NFL Network, as well as the timely launch of ESPN's flagship service, supported the analyst's rating. Diamond Hill Capital, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Other top Q2 contributors included The Walt Disney Company (NYSE:DIS), Ferguson Enterprises and Capital One Financial. Diversified media and entertainment company Walt Disney benefited from easing macroeconomic concerns, primarily in its parks division, which is particularly sensitive to the economic backdrop.' While we acknowledge the potential of DIS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
DA Davidson Raises Target on AppFolio (APPF) After Strong Earnings and AI Innovations
AppFolio, Inc. (NASDAQ:APPF) is one of the best growth stocks to buy according to analysts. On August 6, DA Davidson maintained its Buy rating on AppFolio, Inc. (NASDAQ:APPF), while increasing its price target from $350 to $375. That represents a whopping 41.3% implied upside according to DA Davidson. The firm's analysts met with the company's VP of Finance, Bill Schroeder, post which DA Davidson seemed confident about AppFolio's ability to monetize the value it provides to residents and property managers through its apps and websites. The firm thinks that AppFolio will be able to capture even more market share through product innovation, pricing and packaging. In 2025, the company is pioneering AI-powered solutions that empower teams to work smarter and build stronger communications. With leasing becoming more complicated, the company launched AppFolio Leasing CRM on May 30, 2025. This is helping streamline the leasing process and improve team communication for property managers. Earlier this month, the stock galloped over 20% after it reported earnings on July 31. AppFolio reported a revenue of $235.57, growing 19.3% year-over-year, while beating estimates. It surprised Wall Street by reporting an EPS of $1.38 per share, which is 7.5% more than the analysts' estimates of $1.28 per share. While we acknowledge the potential of APPF as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
New York Times
6 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
